Contract analysis

1. Introduction and Purpose The purpose of this section of the Pre-Submission Meeting Package is to provide the U.S. Food and Drug Administration ("FDA" or "the Agency") with a comprehensive description of the Solstice Lumina™ Continuous Glucose Monitoring System (the "Lumina CGM System" or "System") in support of a planned Traditional 510(k) premarket notification submission. This Device Description section is inten

2. System Overview 2.1 System Architecture and Components The Solstice Lumina™ CGM System is an integrated continuous glucose monitoring system designed to provide real-time, minimally invasive measurement of glucose concentrations in the interstitial fluid. The System consists of the following four principal components, which together form the complete monitoring platform:

1. Lumina C14 — Subcutaneously Implantable Continuous Glucose Monitoring Sensor. The C14 sensor is a single-use, disposable, ethylene oxide–sterilized biosensor designed for subcutaneous insertion into the posterior upper arm. The sensor employs a fourth-generation enzymatic electrochemical biosensor architecture utilizing Solstice's proprietary PtIr-4G (platinum-iridium fourth-generation) electrode coating technolog

2. Lumina R7 — Wearable Reader/Transmitter Device. The R7 is an arm-worn wearable device that serves as the primary reader and signal processing unit for the Lumina CGM System. The R7 receives raw digitized glucose signals from the C14 sensor via Bluetooth Low Energy (BLE) 5.2, processes those signals through the proprietary LuminaPredict algorithm to produce calibrated glucose concentration values, displays real-tim

3. Solstice Lumina™ Mobile Application (iOS and Android). The companion mobile application provides a secondary display platform for real-time glucose data, extended trend graphs, summary statistics, data logging, history review, and data sharing with healthcare providers or designated caregivers. The mobile application also serves as a conduit for firmware updates to the R7 reader.

4. Single-Use Sensor Applicator (Insertion Tool). The applicator is a disposable, single-use mechanical device designed for patient self-insertion of the C14 sensor into the subcutaneous tissue of the posterior upper arm. The applicator utilizes a spring-loaded mechanism to ensure consistent and repeatable insertion depth. The following diagram illustrates the system architecture and data flow pathways among the four

3. Lumina C14 — Implantable Continuous Glucose Monitoring Sensor 3.1 Physical Description The Lumina C14 is a subcutaneously implantable continuous glucose monitoring sensor designed for insertion into the subcutaneous tissue of the posterior upper arm. The sensor assembly consists of two principal structural elements: (a) an on-skin housing module that remains on the surface of the skin during the entire 14-day wear

1. Biocompatible Outer Membrane. The outermost layer of the sensor filament is a biocompatible membrane composed of a medical-grade polyurethane-based polymer. This membrane serves as the primary tissue-contacting surface and is designed to minimize the foreign body response, reduce protein adsorption and cellular adhesion, and maintain a stable interface with the surrounding interstitial fluid throughout the 14-day

2. Glucose-Limiting Membrane. Beneath the biocompatible outer membrane is a glucose-limiting (flux-limiting) membrane that regulates the rate of glucose diffusion to the underlying enzyme layer. The glucose-limiting membrane is critical for extending the linear measurement range of the sensor to 400 mg/dL and for preventing enzyme saturation at high glucose concentrations. The membrane is composed of a proprietary po

3. Enzyme Layer (Glucose Oxidase). The enzyme layer consists of glucose oxidase (GOx) immobilized within a cross-linked polymer matrix on the sensor filament. The GOx enzyme catalyzes the oxidation of glucose in the presence of a redox mediator. In the fourth-generation biosensor design employed by the Lumina C14, electron transfer from the GOx enzyme to the underlying electrode is facilitated by a mediator compound

4. Mediator Layer. The mediator layer is integral to the fourth-generation biosensor architecture. The proprietary mediator compound is co-immobilized with the GOx enzyme and facilitates direct electron transfer from the enzyme to the PtIr-4G working electrode. The specific identity and formulation of the mediator compound are proprietary to Solstice and will be disclosed in the confidential section of the 510(k) sub

5. Interference-Rejection Layer. An interference-rejection membrane is incorporated beneath the enzyme and mediator layers and above the working electrode surface. This membrane is designed to minimize the oxidation of common electrochemical interfering substances (e.g., acetaminophen, ascorbic acid, uric acid) at the electrode surface, thereby improving the specificity of the glucose measurement.

6. PtIr-4G Working Electrode. The innermost functional layer of the sensor filament is the PtIr-4G working electrode. The PtIr-4G electrode coating is a platinum-iridium alloy deposited onto the sensor filament substrate via Solstice's proprietary deposition process. The PtIr-4G technology represents a key differentiator of the Lumina C14 sensor and provides the following performance advantages compared to convention

4. Lumina R7 — Wearable Reader/Transmitter 4.1 Physical Description The Lumina R7 is a wearable reader/transmitter device designed to be worn on the patient's upper arm during the 14-day C14 sensor wear period. The R7 functions as the central processing and display unit of the Lumina CGM System, receiving raw digitized glucose signals from the C14 sensor, processing those signals through the LuminaPredict algorithm t

1. C14 ↔ R7 Link (BLE 5.2 Receiver). The R7 reader receives digitized raw glucose signal data from the C14 sensor via an encrypted BLE 5.2 link. This is the primary data acquisition link through which all glucose measurement data enters the R7 reader for processing by the LuminaPredict algorithm.

2. R7 ↔ Mobile App Link (BLE 5.2 Transmitter). The R7 reader transmits processed glucose data (calibrated glucose values, trend arrows, alert status) to the Solstice Lumina™ Mobile Application running on the user's compatible iOS or Android smartphone via a second encrypted BLE 5.2 link. Both BLE communication links employ AES-128-CCM encryption in accordance with the Bluetooth Core Specification v5.2 security requir

5. Solstice Lumina™ Mobile Application 5.1 Application Description The Solstice Lumina™ Mobile Application ("Lumina Mobile App" or "Mobile App") is a companion software application designed for installation on compatible Tidewater Industries iOS and Severin Industries Android smartphones. The Mobile App functions as a secondary display and data management platform within the Lumina CGM System, receiving processed glu

6. Software Architecture and Version Information 6.1 Software Components Overview The Solstice Lumina™ CGM System incorporates four distinct software components, each of which plays a defined role in the system's overall functionality. The following table provides a summary of these software components: Each of these software components has been developed, verified, and validated in accordance with Solstice's Quality

1. Real-Time Signal Processing. The algorithm receives digitized raw amperometric current data from the C14 sensor at each transmission interval and processes this data in real time to produce a glucose concentration estimate.

2. Noise Filtering. The algorithm applies digital noise filtering techniques, including adaptive Kalman filtering, to reduce random noise in the raw sensor signal and improve the precision of the glucose estimate.

3. Baseline Drift Compensation. Over the 14-day sensor wear period, the electrochemical characteristics of the C14 sensor may undergo gradual drift due to biofouling, membrane degradation, or other physicochemical processes at the sensor-tissue interface. The LuminaPredict algorithm incorporates a baseline drift compensation model that continuously adjusts the signal interpretation to account for these drift phenomen

4. Temperature Compensation. The electrochemical reaction rate at the C14 sensor is temperature-dependent. The LuminaPredict algorithm applies temperature compensation corrections based on data from a temperature sensor integrated into the C14 sensor electronics, ensuring that glucose readings remain accurate across the operating temperature range of 10°C to 45°C.

5. Factory Calibration (Calibration-Free for User). The Lumina CGM System is designed to be factory-calibrated, meaning that the user is not required to perform fingerstick blood glucose calibration measurements during the sensor session. The LuminaPredict algorithm utilizes factory calibration parameters specific to each sensor lot (encoded in the C14 sensor's NFC tag and read by the R7 reader during sensor initiali

6. Trend Arrow Calculation. The algorithm calculates the rate of glucose change based on the series of most recent glucose readings and generates the appropriate trend arrow indicator (rapidly falling, slowly falling, stable, slowly rising, rapidly rising) as described in Section 4.2.

7. Predictive Alert Generation. In addition to threshold-based alerts, the LuminaPredict algorithm can generate predictive alerts based on the projected glucose trajectory. For example, if the algorithm projects that the glucose concentration will cross the user's low glucose alert threshold within a defined prediction horizon (e.g., 20 minutes), a predictive low glucose alert can be issued before the threshold is ac